Contemporary Management of Dyslipidemia
- PMID: 35303294
- PMCID: PMC8931779
- DOI: 10.1007/s40265-022-01691-6
Contemporary Management of Dyslipidemia
Abstract
The treatment of dyslipidemia continues to be a dynamic and controversial topic. Even the most appropriate therapeutic range for lipid levels-including that of triglycerides and low-density lipoprotein cholesterol-remain actively debated. Furthermore, with ever-increasing options and available treatment modalities, the management of dyslipidemia has progressed in both depth and complexity. An understanding of appropriate lipid-lowering therapy remains an essential topic of review for practitioners across medical specialties. The goal of this review is to provide an overview of recent research developments and recommendations for patients with dyslipidemia as a means of better informing the clinical practice of lipid management. By utilizing a guideline-directed approach, we provide a reference point on optimal lipid-lowering therapies across the spectrum of dyslipidemia. Special attention is paid to long-term adherence to lipid-lowering therapies, and the benefits derived from instituting appropriate medications in a structured manner alongside monitoring. Novel therapies and their impact on lipid lowering are discussed in detail, as well as potential avenues for research going forward. The prevention of cardiovascular disease remains paramount, and this review provides a roadmap for instituting appropriate therapies in cardiovascular disease prevention.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Conflict of interest statement
RAF, none. TL, grants from the American Heart Association Career Development Award (19CDA34760040), the Johns Hopkins Center for AIDS Research (P30AI094189 and 1704611701), the Johns Hopkins Older Americans Independence Center (P30AG021334), and Amgen. SSM has served as a consultant Quest Diagnostics, Sanofi/Regeneron, Amgen, and the Pew Research Center. MB, speakers bureau: Amgen, Daichii Sankyo, Herbapol, Kogen, KRKA, Mylan, Novartis, Novo-Nordisk, Polpharma, Sanofi, Servier, Teva, Zentiva; consultant to Amgen, DaichiiSankyo, Esperion, Freia Pharmaceuticals, Mylan, Polfarmex, Sanofi/Regeneron, Teva; Grants from Amgen, Mylan, Sanofi, and Valeant. SSM and SRJ are listed as coinventors on a pending patent filed by Johns Hopkins University for LDL-C estimation. SRJ has served as an advisor to Sanofi/Regeneron. PPT, speaker’s bureau: Amarin, Amgen, Esperion, Novo-Nordisk; Consultant: Amarin, Esperion, Kowa, Merck, Resverlogix, Theravance.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
